JPMorgan Chase & Co. started coverage on shares of Health Catalyst (NASDAQ:HCAT) in a research note issued to investors on Monday, BenzingaRatingsTable reports. The firm issued an overweight rating and a $50.00 target price on the stock.

Several other research firms have also recently commented on HCAT. SunTrust Banks began coverage on shares of Health Catalyst in a research report on Monday. They issued a buy rating and a $53.00 target price for the company. William Blair began coverage on shares of Health Catalyst in a report on Monday. They issued an outperform rating for the company. Evercore ISI began coverage on shares of Health Catalyst in a report on Monday. They issued an outperform rating and a $50.00 price objective for the company. Piper Jaffray Companies began coverage on shares of Health Catalyst in a report on Monday. They issued an overweight rating and a $47.00 price objective for the company. Finally, Leerink Swann began coverage on shares of Health Catalyst in a report on Monday. They issued an outperform rating and a $55.00 price objective for the company. Eight equities research analysts have rated the stock with a buy rating, The stock has a consensus rating of Buy and a consensus target price of $51.29.

NASDAQ HCAT opened at $42.94 on Monday. Health Catalyst has a 52 week low of $36.29 and a 52 week high of $49.85.

Health Catalyst Company Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations. Its products include analytics platform, accountable care and financial, benchmarking and comparative analytics, care management and population health, clinical analytics, operations and performance management, patient safety, and services.

Further Reading: What is a balanced fund?

Analyst Recommendations for Health Catalyst (NASDAQ:HCAT)

Receive News & Ratings for Health Catalyst Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Health Catalyst and related companies with MarketBeat.com's FREE daily email newsletter.